Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects

Fig. 3

Change-from-baseline in QTcF across time points and study treatments. Mean ΔQTcF on lucerastat closely followed the pattern observed on placebo with no indication of dose dependency, whereas moxifloxacin caused a clear QTc prolongation. a Effect of study treatments on ΔQTcF. b Effect of study treatments on ΔΔQTcF. Data expressed as LS mean and 90% CI based on a linear mixed-effects model. The dashed black lines represent the threshold for clinically concerning QTc prolongation. CI, confidence interval; Δ, change-from-baseline; ΔΔ, placebo-corrected change-from-baseline; LS, least squares; QTcF, Fridericia-corrected QTc

Back to article page